Despite the tough market conditions for the industry over the past 2–3 years, the biotechnology sector is poised for big things moving forward. Exciting advances in precision genome editing, cell therapy, synthetic biology, organs-on-chips, next-gen sequencing and artificial intelligence all bode well for the development of new therapies and the health of patients and the industry. In The State…
Amgen enjoyed its biggest one-day stock gain since 2009 after top executives delivered positive comments about its obesity candidate MariTide.
Federico Mingozzi, PhD, joins Allison Keeler, PhD, on GEN Live to discuss the state of gene therapy and what they are looking forward to at…
CRISPR gene editing leads to improvements in vision for people with inherited blindness, a recent clinical trial shows.
In vitro-transcribed mRNAs have been proven efficient in various therapeutic applications. However, manufacturing them poses challenges due in part to complexity of the molecules as…
Enzymes from gut bacteria open a new path to universal donor blood by efficiently clearing glycans from red blood cells.
Tumors of epigenetic, not genetic, origin have been demonstrated, challenging the established idea that cancer is caused only by permanent changes to DNA
Addition of B. subtilis spores also pushed mechanical properties of plastic beyond known limitations, addressing trade off between tensile strength and stretchability
The BEQVEZ gene therapy inserts a working copy of the Factor IX (FIX) gene that codes for a high-activity FIX variant.
Prime Medicine said it has gained FDA clearance for the first human trials of a prime editing therapy as the agency has approved an investigational…
What we know so far about the H5N1 influenza strain, otherwise known as “bird flu” or “avian flu,” and its spread in the United States.
